Omeros Co. (NASDAQ:OMER)’s share price was down 2.3% during mid-day trading on Thursday . The stock traded as low as $14.31 and last traded at $14.15. Approximately 448,124 shares traded hands during mid-day trading, a decline of 36% from the average daily volume of 702,502 shares. The stock had previously closed at $14.49.
Several equities analysts have issued reports on OMER shares. HC Wainwright set a $30.00 price target on shares of Omeros and gave the company a “buy” rating in a research report on Thursday, December 14th. Maxim Group set a $24.00 price target on shares of Omeros and gave the company a “buy” rating in a research report on Tuesday, December 12th. Finally, Zacks Investment Research cut shares of Omeros from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $34.14.
The company has a debt-to-equity ratio of 8.99, a current ratio of 4.77 and a quick ratio of 4.74. The firm has a market cap of $671.57, a PE ratio of -11.01 and a beta of 3.31.
Institutional investors and hedge funds have recently bought and sold shares of the company. C M Bidwell & Associates Ltd. acquired a new stake in shares of Omeros during the fourth quarter worth $106,000. First Interstate Bank acquired a new stake in shares of Omeros during the third quarter worth $108,000. Legal & General Group Plc increased its position in shares of Omeros by 7.8% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 751 shares during the period. Hanseatic Management Services Inc. increased its position in shares of Omeros by 10,919.6% during the third quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 10,592 shares during the period. Finally, Malaga Cove Capital LLC acquired a new stake in shares of Omeros during the fourth quarter worth $242,000. Institutional investors own 50.23% of the company’s stock.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.